Trials / Completed
CompletedNCT05572567
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
An Observational Study Within the CorEvitas Registry to Evaluate Safety and Effectiveness of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs (bDMARDs) in Japan Among Patients Treated for Moderately to Severely Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,972 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a secondary structured database observational study conducted in Rheumatoid Arthritis (RA) patients treated with biologic and nonbiologic DMARDs, including tofacitinib, collected as part of the CorEvitas Japan RA Registry. The data as of September 2022 will be used for this study. The study will include data from March 2016 to the latest data cut available in 2022 for both effectiveness and safety outcomes.
Conditions
Timeline
- Start date
- 2022-10-10
- Primary completion
- 2022-10-10
- Completion
- 2022-10-10
- First posted
- 2022-10-07
- Last updated
- 2025-06-08
- Results posted
- 2025-06-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05572567. Inclusion in this directory is not an endorsement.